MiMedx Reports Positive Clinical Trial Results of AmnioFix for Plantar Fasciitis

On March 26, MiMedx Group, Inc. (MDXG) reported positive results from its Phase 2B IND clinical trial of AmnioFix. In the clinical trial, patients who received the AmnioFix Injectable treatment for their Plantar Fasciitis had a clinically and statistically significant improvement when compared to the control group. Plantar Fasciitis is the most common cause of heel pain in adults.

 

Rocket Tickers detected the event and sent an alert to its subscribers at 9:40 am. The next trade took place for $6.93 at 9:41 am. The stock closed at $7.25 on the day of the news event.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!

SaveSave